Citracal Deal Will Move Bayer Into U.S. Calcium Market, Expand Portfolio
This article was originally published in The Tan Sheet
Executive Summary
Bayer's Healthcare Consumer Care Division expects to expand its global OTC calcium market offerings through its planned acquisition of Mission Pharmacal's Citracal brand, according to company executives who also say the move will help the firm continue diversifying its nutritional product portfolio
You may also be interested in...
Reckitt’s Schiff Buy Reflects Nutritional Industry “On Fire”
Reckitt Benckiser went high with its $1.4 billion bid for Schiff Nutrition, though the acquisition’s impressive multiples are not entirely out of line with earlier deals in the nutrition space. Analyst Damian Witkowski notes that Airborne, MegaRed and other Schiff brands already are primed for organic growth.
Reckitt’s Schiff Buy Reflects Nutritional Industry “On Fire”
Reckitt Benckiser went high with its $1.4 billion bid for Schiff Nutrition, though the acquisition’s impressive multiples are not entirely out of line with earlier deals in the nutrition space. Analyst Damian Witkowski notes that Airborne, MegaRed and other Schiff brands already are primed for organic growth.
Bayer acquires supplement brand
Bayer HealthCare's Consumer Care division has received regulatory approval to acquire Mission Pharmacal's Citracal calcium supplements, Morristown, N.J.-based Bayer Consumer Care reports Oct. 5. The transaction, which closed Oct. 4, increases the Consumer Care division's market presence in the U.S., Bayer noted. The firm will continue to build upon Citracal's "already strong nutritionals business," which includes leading brands such as One-A-Day, Bayer notes. Primarily sold in North America, the brand generated net sales of $47 mil. in San Antonio-based Mission's fiscal 2007. Bayer announced plans to acquire Citracal in August (1"The Tan Sheet" Sept. 3, 2007, p. 11)...